Loading…
Live market data via Yahoo Finance · updated 7/31/2026
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines for patients living with rare diseases in the United States.
It offers Firdapse for the treatment of Lambert-Eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic AMPA receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc.
was founded in 2002 and is based in Coral Gables, Florida.
Catalyst Pharmaceuticals, Inc. (CPRX) is currently trading at $31.49 per share with a market cap of $3.85B, ranking 1519.
The price outlook presents a rising trajectory in the forecast horizon, with a 2026 average of $31.49 and a 2027 average of $40.25 (ROI 27.8%), followed by a 2028 average of $44.58 (ROI 41.6%) and a 2029 average of $57.37 (ROI 82.2%), leading to a 2030 average of $73.28 (ROI 132.7%).
Beyond 2030, the forecast continues higher, with 2031 average $80.47 (ROI 155.5%), 2032 $94.84 (ROI 201.2%), 2033 $104.44 (ROI 231.7%), 2034 $108.79 (ROI 245.5%), and 2035 $125.57 (ROI 298.8%), then 2040 average $210.78 (ROI 569.4%) and 2050 average $495.36 (ROI 1473.1%). The sentiment in these years is bullish from 2027 onward, reflecting an optimistic long-term outlook.
A major floor 29.1% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 0.5% above — clearing it would confirm fresh momentum.
Key CPRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CPRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $31.49 | Buy | $31.49 | Buy |
| MA 10 | $31.48 | Buy | $31.48 | Buy |
| MA 20 | $31.47 | Buy | $31.44 | Buy |
| MA 50 | $31.35 | Buy | $30.71 | Buy |
| MA 100 | $28.41 | Buy | $29.03 | Buy |
| MA 200 | $25.64 | Buy | $26.76 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 70.14 | Sell |
| Stoch RSI (14) | 36.11 | Neutral |
| CCI (20) | 60.49 | Neutral |
| Williams %R (14) | -16.67 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | 0.13 | Buy |
| Bollinger %B (20,2) | 0.69 | Neutral |
| Stochastic %K (14) | 83.33 | Sell |
| TRIX (15) | 0.06 | Buy |
| Awesome (5,34) | 0.08 | Buy |
| Ultimate (7,14,28) | 88.10 | Sell |
| Momentum (10) | 0.00 | Neutral |
| Aroon Osc (25) | 48.00 | Buy |
| Hull MA (9) | 31.49 | Sell |
| ADX (14) | 41.34 | Buy |
| ATR (14) | 0.03 | Info |
The 30-day technical picture shows a tight near-term range with a low of $29.71 and a high of $33.37.
RSI(14) is 70, indicating near-term bullish momentum. The 50-day moving average (SMA50) is $31.35, while the 200-day moving average (SMA200) sits at $25.64. Support is reported at $31.28 and resistance at $31.50, framing a near-term trading band around the mid-$30s. The overall sentiment is BULLISH.
See what a past investment in CPRXwould be worth at today's price.
$1,000 invested in CPRX on Jul 21, 2025 (≈ 47.596382 CPRX) would be worth
$1,498.81
+$498.81 (+49.9%) today · 1.50× · US Dollar
Based on a CPRX entry price of $21.01 vs. today's $31.49.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $31.49 | $1,000 | +0.0% |
| 1 month ago | $31.38 | $1,003.51 | +0.4% |
| 3 months ago | $25.94 | $1,213.96 | +21.4% |
| 6 months ago | $24.45 | $1,287.93 | +28.8% |
| 1 year ago | $21.01 | $1,498.81 | +49.9% |
| All time (5.0y) ago | $5.9 | $5,337.29 | +433.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
The multi-year forecast points to substantial upside for CPRX. In 2026 the avg price is $31.49, rising to $73.28 by 2030, with a max of $99.84 and an ROI of 132.7% at that horizon, all within a bullish context.
From 2031 onward, the averages continue higher—$80.47 in 2031, $94.84 in 2032, $104.44 in 2033, $108.79 in 2034, and $125.57 in 2035—before escalating to $210.78 in 2040 and $495.36 in 2050. These years carry bullish sentiment and ROIs extending into three-digit figures (e.g., 155.5% in 2031, 201.2% in 2032, 231.7% in 2033, 245.5% in 2034, 298.8% in 2035, 569.4% in 2040, and 1473.1% in 2050).
These are estimates, not guarantees; actual results will depend on a range of market and company-specific factors. Investors should weigh the upside potential against inherent uncertainties in long-term forecasts.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $73.28 with a max of $99.84 and an ROI of 132.7%, with bullish sentiment.
Current price is $31.49 and market cap is $3.85B, with a rank of 1519.
The 2030 max is $99.84, which is slightly under $100, indicating it would not reach $100 by 2030 according to this forecast.
Avg $495.36; max $809.80; ROI 1473.1%; sentiment bullish.
Yes. The forecast shows bullish sentiment from 2027 onward, with 2026 neutral, indicating a long-term bullish outlook.
Catalyst Pharmaceuticals Inc Community Discussion
0Share your Catalyst Pharmaceuticals Inc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.